ArticleJMA journal2026
Real-world Practice Patterns and Barriers to SGLT2 Inhibitor Use: A Nationwide Survey of Japanese General Practitioners.
Article in JMA journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Sodium-glucose cotransporter 2 (SGLT2) inhibitors were approved for the treatment of chronic kidney disease (CKD) in Japan in 2021. However, their use remains limited, and broader implementation is necessary to improve CKD outcomes. Methods: A questionnaire survey on the diagnosis and treatment of CKD was conducted among members of the Japan Physicians Association and local internal medicine associations. Based on responses regarding the use of SGLT2 inhibitors in patients with CKD, respondents excluding nephrologists were classified into two groups: the Active User group (n = 508) and the Passive User group (n = 316). The responses were compared between groups, and independent factors associated with active use were analyzed using logistic regression analysis. Results: Compared with the Passive User group, respondents in the Active User group were younger (p = 0.047). Specialization in cardiology, allergy, use of serum cystatin C to evaluate kidney function, utilization of urine testing, use of estimated glomerular filtration rate and kidney imaging to define CKD, frequent assessment of quantitative albuminuria, evaluation of hemoglobin and transferrin saturation levels to assess renal anemia, prescription of hypoxia-inducible factor prolyl hydroxylase inhibitors, implementation of dietary therapy for patients with non-dialysis CKD, referral to nephrologists for both proteinuria and hematuria, and consultation for proteinuria >1.0 g/gCr or ≥2+ by qualitative testing were all positively associated with the Active User group, with odds ratios of 1.84, 6.13, 2.05, 34.8, 1.96, 4.52, 1.72, 2.10, 2.56, 2.03, and 2.62, respectively. Conclusions: Among non-nephrologists, difference in the active prescription of SGLT2 inhibitors for patients with CKD was associated with a comprehensive and guideline-based approach to CKD management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.